Omberacetam

SKU: orb1300065

Description

Omberacetam

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 157115-85-0
• MW: 318.37
• Purity: ≥95%
• Formula: C₁₇H₂₂N₂O₄
• SMILES: CCOC(=O)CNC(=O)C1CCCN1C(=O)CC1=CC=CC=C1
• Target: iGluR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (12.56 mM);DMSO:100 mg/mL (314.1 mM)

Bioactivity

• In Vivo:
  Noopept eliminate the manifestations of learned helplessness after long-term (21-day) treatment by increasin the percent of trained animal.
• In Vitro:
  The neuro Protective effect of noopept (added to the medium at 10 μM concentration 72 hours before Аβ 25-35) was studied on Аβ 25-35-induced injury (5 μM for 24 h) in PC12 cells the ability of drug to protec the impairments of cell viability, calcium homeostasis, ROS level, mitochondrial function, tau phosphorylation and neurite outgrowth caused by Аβ 25-35 were evaluated. Followin the exposure of PC12 cells to Аβ 25-35 an increase o the level of ROS, intracellular calcium, and tau phosphorylation at Ser396 were observed; these changes were accompanied by a decrease in cell viability and an increase of apoptosis. Noopept treatment befor the amyloid-beta exposure improved PC12 cells viability, reduce the number of early and late apoptotic cells the levels of intracellular Reactive oxygen species and calcium and enhance the mitochondrial membrane potential. In addition, pretreatment of PC12 cell with noopept significantly attenuated tau hyperphosphorylation at Ser396 and ameliorate the alterations of neurite outgrowth evoked by Аβ25-3.
• Cell Research:
  PC12 cells were cultured routinely at 37℃n DMEM medium, supplemented with 10% fetal bovine serum (FBS), 5% horse serum, 2 mM L-glutamine, 50 μg mL gentamicin. To induce PC12 differentiation, NGF (50 ng/mL) was added to the DMEM containing 1% FBS, followed by a 5-day incubation. Differentiated PC12 (dPC12) cells were pretreated with noopept at concentration of 10 μM for 72 h, then cells were rinsed wit the medium and exposed to amyloid-β-peptide (Аβ25–35;5 μM) for 24 h. Untreated cells were used as contro.
• Animal Research:
  Experiments were carried out on adult outbred albino Male rats ( = 76; 250-300 g) kept under vivarium conditions with 12 h light period with free access to water and s andard food the operant training was performed in a modified setup for active avoidance conditioning under conditions of uncertain envir nMent.The animals were intraperitoneally injected (1 L/kg) with noopept (0.1, 0.5, and 1.0 mg/kg) and piracetam (100, 300, and 500 mg/kg; reference drug), afobazol (1, 5, and 10 mg/kg), and buspiron (0.5, 1.0, and 5.0 mg/kg; reference drug) and diazepam (0.05, 0.1, and 0.5 mg/kg; reference drug). Control rats were injected wit the same volume of saline. Stability of active avoidance behavior was tested after 48 h and 7 days the animals with learned helplessness neurosis were injected with noopept and afobazol for 21 days, after which stability o the active avoidance behavior was repeatedly teste.

Storage & Handling

• Storage: keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

GVS 111, GVS111, GVS-111, iGluR, Omberacetam, Ionotropic glutamate receptors, Inhibitor, inhibit, Noopept, SGS 111, SGS111, SGS-111

Compound Identifiers

PubChem CID

45926902